1,2-diamine bistrisylamides 1 using a chiral π-allyl Pd catalyst
Catalytic Asymmetric Desymmetrization of
meso-Diamide Derivatives through
(eq 1).4,5 This reaction proceeded in the presence of (allyl-Pd-
Enantioselective N-Allylation with a Chiral
π-Allyl Pd Catalyst: Improvement and Reversal
of the Enantioselectivity
Osamu Kitagawa, Shinichi Matsuo, Kanako Yotsumoto, and
Takeo Taguchi*
Tokyo UniVersity of Pharmacy and Life Science, 1432-1
Horinouchi, Hachioji, Tokyo 192-0392, Japan
taguchi@ps.toyaku.ac.jp; kitagawa@ps.toyaku.ac.jp
ReceiVed December 2, 2005
Cl)2 and (R,R)-Trost ligand to give N-monoallylated (asymmetric
desymmetrization) products 2 in 71-90% ee. We also succeeded
in the conversion of asymmetric desymmetrization product 2a
[R ) R ) (CH2)4] to σ-receptor agonist 3 (eq 1).3a The present
reaction is the first example of asymmetric desymmetrization
with meso-diamine derivatives.6,7 In addition, it should be
noteworthy that among transition metal-catalyzed N-C bond-
forming reactions, this reaction is a rare example of asymmetric
induction at the nitrogen nucleophile site (enantiocontrol of
prochiral nitrogen nucleophile).8 In this paper, we report the
improvement of the enantioselectivity by screening the Trost
In the presence of the Trost ligands-Pd catalysts, N-
monoallylation of bis(2,4,6-triisopropylbenzne)sulfonyl-
amides derived from meso-1,2-diamines proceeds with good
to excellent enantioselectivity (85-96% ee) to give asym-
metric desymmetrization products. Under the same condi-
tions, in the reaction with meso-bistolunesulfonylamide
derivatives, reversal of the enantioselectivity is observed.
(3) (a) Radesca, L.; Bowen, W. D.; Paolo, L. D.; De Costa, B. R. J.
Med. Chem. 1991, 34, 3058. (b) De Costa, B. R.; Dominguez, C.; He, X.;
Williams, W.; Radesca, L.; Bowen, W. J. Med. Chem. 1992, 35, 4334. (c)
Novakova, M.; Ela, C.; Bowen, W. D.; Hasin, Y.; Eilam, Y. Eur. J.
Pharmacol. 1998, 353, 315. (d) Hong, W.; Werling, L. L. Eur. J. Pharmacol.
2002, 436, 35. (e) Govindaraju, T.; Gonnade, R. G.; Bhadbhade, M. M.;
Kumar, V. A.; Ganesh, K. N. Org. Lett. 2003, 5, 3013. (f) Govindaraju, T.;
Kumar, V. A.; Ganesh, K. N. J. Org. Chem. 2004, 69, 5725. (g) Govindaraju,
T.; Kumar, V. A.; Ganesh, K. N. J. Am. Chem. Soc. 2005, 127, 4144.
(4) Kitagawa, O.; Yotsumoto, K.; Kohriyama, M.; Dobashi, Y.; Taguchi,
T. Org. Lett. 2004, 6, 3605.
(5) For reviews on catalytic asymmetric allylation with a chiral π-al-
lylpalladium complex see: (a) Hayashi, T. In Catalytic Asymmetric
Synthesis; Ojima, I., Ed.; VCH Publishers: New York, 1994; pp 325-
365. (b) Trost, B. M.; Van Vranken, D. L. Chem. ReV. 1996, 96, 395.
(6) To the best of our knowledge, there has been no report on asymmetric
desymmetrization of meso-diamine derivatives. In the reaction with diamine
substrates, the enantiocontrol may be difficult because of high nucleophilicity
of the amino group and the strong ability to chelate with transition metal,
which may result in dissociation of the chiral ligand from the catalytic center
and deactivation of the catalyst.
(7) In contrast to diamine derivatives, catalytic asymmetric desymme-
trization of meso-diols has been well-known. (a) Vedejs, E.; Daugulis, O.;
Diver, S. T. J. Org. Chem. 1996, 61, 430. (b) Oriyama, T.; Imai, K.; Sano,
T.; Hosoya, T. Tetrahedron Lett. 1998, 39, 397. (c) Kawabata, T.; Stragies,
R.; Fukuya, T.; Nagaoka, Y.; Schedel, H.; Fuji, K. Tetrahedron Lett. 2003,
44, 1545. (d) Matsumura, Y.; Maki, T.; Murakami, S.; Onomura, O. J. Am.
Chem. Soc. 2003, 125, 2052. (e) Trost, B. M.; Mino, T. J. Am. Chem. Soc.
2003, 125, 2410. (f) Shimizu, H.; Katsuki, T. Chem. Lett. 2003, 32, 480.
(g) Mizuta, S.; Sadamori, M.; Fujimoto, T.; Yamamoto, I. Angew. Chem.,
Int. Ed. 2003, 42, 3383. (h) Mandal, S. K.; Jensen, D. R.; Pugsley, J. S.;
Sigman, M. S. J. Org. Chem. 2003, 68, 4600. (i) Mizuta, S.; Tsuzuki, T.;
Fujimoto, T.; Yamamoto, I. Org. Lett. 2005, 7, 3633. (j) For a review see:
Willis, M. C. J. Chem. Soc., Perkin Trans. 1 1999, 1765.
Organic compounds possessing a diamine functionality have
played an important role in the field of medicinal and synthetic
chemistry.1 Various optically active synthetic diamine deriva-
tives have been employed as chemotherapeutic agents or as
chiral ligands for asymmetric reaction.1 Accordingly, numerous
synthetic methods for optically active diamine derivatives have
been developed,1 while the asymmetric synthesis of these
diamine derivatives through a catalytic enantioselective reaction
has been limited to only a few examples.2 Especially, until now
catalytic asymmetric synthesis of chiral cyclic syn-diamines such
as unsymmetrical cis-1,2-diaminocycloalkanes has been uncom-
mon. It is also noted that chiral compounds possessing a cis-
1,2-diaminocyclohexane and -cyclopentane skeleton have re-
ceived attention as potent medicinal agents.3
Recently, we found a new method for the preparation of
optically active unsymmetrical cis-1,2-diaminocycloalkane de-
rivatives through enantioselective N-monoallylation of meso-
* Address correspondence to this author. FAX and phone: +81-426-76-3257.
(1) (a) Michalson, E. T.; Szmuszkovicz, J. Prog. Drug Res. 1989, 33,
135. (b) Lucet, D.; Le Gall, T.; Mioskowski, C. Angew. Chem., Int. Ed.
1998, 37, 2580.
(2) (a) Li, Z.; Ferna´ndez, M.; Jacobsen, E. N. Org. Lett. 1999, 1, 1611.
(b) Yamada, K.; Moll, G.; Shibasaki, M. Synlett 2001, 980. (c) Ooi, T.;
Sakai, D.; Takeuchi, M.; Tayama, E.; Maruoka, K. Angew. Chem., Int. Ed.
2003, 42, 5868. (d) Trost, B. M.; Fandrick, D. R. J. Am. Chem. Soc. 2003,
125, 11836. (e) Chune, D.; Alper, H. Tetrahedron: Asymmetry 2004, 15,
1537.
(8) (a) Kitagawa, O.; Kohriyama, M.; Taguchi, T. J. Org. Chem. 2002,
67, 8682. (b) Terauchi, J.; Curran, D. P. Tetrahedron: Asymmetry 2003,
14, 587. (c) Kitagawa, O.; Takahashi, M.; Yoshikawa, M.; Taguchi, T. J.
Am. Chem. Soc. 2005, 127, 3676.
10.1021/jo052488y CCC: $33.50 © 2006 American Chemical Society
Published on Web 02/18/2006
2524
J. Org. Chem. 2006, 71, 2524-2527